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OBJECTIVES We sought to determine whether strategies to reduce procedural distal embolization and late
repeat revascularization have resulted in more favorable outcomes after saphenous vein graft
(SVG) angioplasty.
BACKGROUND Angioplasty of SVG lesions has been associated with frequent procedural and late cardiac
events. Therefore, evolving strategies have been attempted to improve outcomes after SVG
angioplasty.
METHODS We compared our earlier experience (1990 to 1994) of 1,055 patients with 1,412 SVG lesions
with a recent group (1995 to 1998) of 964 patients with 1,315 lesions.
RESULTS Baseline characteristics were similar between the groups. However, there were significantly
more unfavorable lesion characteristics (older, longer and significantly more degenerated
SVGs) in the recent series. Between the two periods, there was decreased use of atheroablative
devices, whereas stent use increased. The procedural success rates (96.6% vs. 96.1%) were
similar. However, one-year outcome (event-free survival) was significantly improved in the
more recent experience (70.7% vs. 59.1%, p , 0.0001), especially late mortality (6.1% vs.
11.3%, p , 0.0001). Multivariate analysis showed stent use to be the only protective variable
for both periods.
CONCLUSIONS This study shows that despite higher risk lesions, strategies to reduce distal embolization have
maintained high procedural success. Late cardiac events, including mortality, have also been
substantially reduced. (J Am Coll Cardiol 2001;38:150–4) © 2001 by the American College
of Cardiology
Conventional angioplasty of saphenous vein graft (SVG)
stenosis has been associated with frequent procedural com-
plications due to distal embolization (1), as well as adverse
long-term outcomes due to high rates of target and nontar-
get lesion revascularization (2). Despite these limitations,
SVG angioplasty cannot be abandoned because of the finite
longevity of SVGs, as well as the increased risk and less
symptomatic relief of repeat coronary artery bypass graft
surgery in these patients (3–5). Therefore, over the past
decade, we have adopted evolving strategies to minimize the
risk of distal embolization during the initial procedure to
improve the early outcome and reduce late restenosis, and
possibly progression of disease, for better long-term results.
Our initial hypothesis from 1990 to 1994 was that removal
of the atherosclerotic and thrombotic material using the
atherectomy devices (directional atherectomy and translu-
minal extraction atherectomy) might reduce distal emboli-
zation. However, from 1995 to 1998, we had to revise our
strategy, as the bulky atherectomy devices did not reduce
distal embolization. We hypothesized that minimizing the
instrumentation within the diseased SVG and implanting
stents wherever feasible might improve early and late
outcomes. The objective of the current retrospective study
was to determine whether these evolving strategies have
resulted in more favorable outcomes after SVG angioplasty
over the past decade.
METHODS
Study groups. We compared the baseline demographic
data, lesion characteristics, angioplasty device use patterns,
procedural results and one-year outcomes between the
earlier experience (1990 to 1994) of 1,055 patients with
1,412 SVG lesions and the recent group (1995 to 1998) of
964 patients with 1,315 lesions treated at the Washington
Hospital Center from 1990 to 1998. All patients gave
written, informed consent, and the study was approved by
the institutional Review Board before the procedures. Pro-
cedural success was defined as a final diameter stenosis
,50% in the absence of in-hospital death, Q-wave myo-
cardial infarction (MI) or emergency coronary artery bypass
graft surgery. All patients had creatine kinase, MB isoen-
zyme (CK-MB) levels measured every 8 h after the proce-
dure for at least 24 h in those with no elevation and until its
peak in those with elevation. Non–Q-wave MI was defined
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as CK-MB greater than five times the upper limit of normal
(defined as ,4 mg/dl in our laboratory) in the absence of
new Q waves on the post-intervention electrocardiogram.
Baseline demographic and procedural variables were re-
corded prospectively and entered in the Cardiology Re-
search Foundation data base. All patients were serially
interviewed by experienced research nurses at 1, 3, 6 and 12
months after their procedure. Although the follow-up data
were collected beyond one year after the procedure, the
long-term comparison was intentionally limited to one year
in this study for fair comparison between the groups. The
patients were questioned regarding the occurrence of cardiac
events or the need for repeat coronary revascularization. For
deceased patients, family members and primary care physi-
cians were contacted to try to determine the cause of death.
The cause of death and any cardiac event were adjudicated
from objective documents, whenever possible.
Evolving strategies and rationale. The efforts to minimize
distal embolization during 1990 to 1994 included atherec-
tomy and extraction devices to remove the atherosclerotic
and thrombotic material. However, this strategy did not
improve the early results and did not address the late
outcomes. Thus, starting in 1995, we adopted the following
strategies: 1) avoidance of bulky atheroablative devices; 2)
use of staged procedures in selected degenerated or
thrombus-containing SVG lesions; 3) “direct stenting”
without pre- or post-balloon dilation and avoidance of high
pressure for stent implantation; and 4) judicious use of
glycoprotein IIb/IIIa inhibitors. The rationale for these
approaches is based on the empiric observations that the
SVG lesions seem tenuous and tend to be easily dislodged.
Thus, since 1995, we have attempted to minimize the device
size, as well as the amount of instrumentation within the
graft. In a small percentage (;5% of those in the recent
experience), we improved blood flow during the initial
procedure and provided definitive therapy during the sec-
ond, staged procedure six weeks later (6). More recently,
glycoprotein IIb/IIIa inhibitors have been used both pro-
phylactically in patients with mobile intragraft filling defects
and in a “rescue” manner in patients with reduced Throm-
bolysis In Myocardial Infarction (TIMI) flow or other
evidence of distal embolization during the procedure, al-
though they were used in ,10% of patients.
To reduce the need for late revascularization, we have
used stents whenever feasible since 1995. We routinely
evaluated “intermediate lesions” with intravascular ultra-
sound of the SVG being treated for severe lesions, and we
implanted stents in these angiographically intermediate
lesions if there was evidence of lumen compromise. We also
used stents in distal anastomotic lesions if the distal vessel
was .2.5 mm in diameter (7).
Quantitative and qualitative angiographic analyses. All
cineangiograms at baseline and after angioplasty were ana-
lyzed in a blinded manner with regard to the late outcome,
using the previously published definitions of the qualitative
assessment of lesions (8). Quantitative analysis was per-
formed using a previously published edge-detection algo-
rithm (8) in the projection showing the most severe stenosis
in an unforeshortened view, with the contrast-filled guiding
catheter as the reference standard. Degenerated SVGs were
defined as grafts with ectasia or lumen irregularities com-
prising $50% of the graft length (1).
Statistics. All statistical analyses were performed using the
SAS statistical software (SAS Institute, Cary, North Caro-
lina). Continuous variables are presented as the mean
value 6 SD, and categorical variables as percentages. Com-
parisons between the two groups were made using the
chi-square test or Fisher exact test to analyze differences in
categorical variables, and the Student t test for continuous
variables. Clinical, morphologic and procedural variables
that had demonstrated a statistically significant difference
between the groups were included in the multivariate
logistic regression analyses to identify factors associated
with target lesion revascularization (TLR) or late cardiac
events. A p value ,0.05 was considered significant.
RESULTS
Baseline characteristics. The two groups were similar at
baseline (Table 1). They represent a typical high-risk
angioplasty population, with the majority experiencing un-
stable angina before the intervention, a high prevalence of
previous MI and a relatively high prevalence of diabetes.
Lesion characteristics. In contrast, there were significantly
more unfavorable lesion characteristics in the more recent
group (Table 2). The grafts were older and the lesions were
longer, and notably, there was a significantly greater per-
centage of degenerated SVGs in the recent series compared
with the earlier experience. Angiographic thrombus, how-
ever, was less frequent in the recent group. Quantitative
angiographic analysis showed larger reference and final
lesion lumen diameters in the recent group.
Table 1. Baseline Characteristics of the Study Patients
1990 to 1994
(n 5 1,055)
1995 to 1998
(n 5 964)
Male 78% 77%
Age (yrs) 66 6 9 67 6 10
Unstable angina 81.5% 77.1%
Previous myocardial infarction 64.8% 66.1%
Diabetes mellitus 34% 38%
Left ventricular ejection fraction 41 6 13 42 6 13
Data are presented as the percentage of patients or mean value 6 SD. P values were
not significantly different between the two groups for all variables.
Abbreviations and Acronyms
CK-MB 5 creatine kinase-MB isoenzyme
MI 5 myocardial infarction
SVG 5 saphenous vein graft
TLR 5 target lesion revascularization
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Angioplasty devices and pharmacology. The percentage
of stand-alone balloon procedures was relatively unchanged
between the groups (Table 3). This procedure was reserved
mainly for the distal anastomotic lesions. In contrast, the
use of atheroablative devices, in general, was significantly
reduced between the two periods. The only exception was
the Excimer laser (Spectranetics, Colorado Springs, Colo-
rado), which was used more frequently in the recent group,
with the hope of reducing distal embolization from the
front-end ablation, owing to the lower profile of the device
compared with other atherectomy devices. Stent use has
increased significantly. In fact, the stent has become the
device of choice in the majority of lesions, excluding the
distal anastomotic site. In the early group, the patients
mainly received heparin during the procedure and crossed
over to warfarin with stent use. In the recent group, the
patients received either ticlopidine or clopidogrel after stent
implantation and no warfarin therapy. Abciximab use was
limited to the recent group in a minority of patients (8.7%).
Distal protection device was not used in either group.
In-hospital outcomes. Procedural success was high in
both groups and did not differ much. The major in-hospital
complications, as well as the rates of non–Q-wave MI and
no reflow phenomenon, were similar between the groups
(Table 4).
Late clinical outcomes. One-year outcome was signifi-
cantly improved in the more recent experience (Table 5).
Event-free survival was markedly better, mainly because of
significantly reduced late mortality and TLR. There was an
absolute reduction of almost 5% in late mortality and 7%
absolute reduction in late TLR. The majority (.70%) of
late mortalities in both groups were cardiac in origin,
including sudden out-of-hospital death and uncompensated
heart failure. In contrast, the incidence of non-TLR and
nonfatal Q-wave MI was not significantly different between
the two groups.
Multivariate predictors of late cardiac events. For both
groups, unstable angina was a predictor of late cardiac events
(Table 6). Diabetes was also a negative predictor in the early
group, whereas ostial location was a negative predictor in
the recent group. Stent use was the only protective variable
for both groups.
Multivariate predictors of TLR. For both groups, ostial
location was a negative predictor of TLR (Table 7). For the
early group, age and final minimal lumen diameter were
inversely associated with TLR. Stent use was associated
with reduced TLR only for the recent group.
DISCUSSION
This study shows that the evolving strategies to treat SVG
lesions have maintained high procedural success, despite
high-risk lesions, and have resulted in substantially im-
proved late outcomes, including late mortality and TLR.
Although this is a retrospective study without randomiza-
Table 2. Lesion-Related Characteristics
1990 to 1994
(n 5 1,412)
1995 to 1998
(n 5 1,315) p Value
Graft age (months) 95 6 53 100 6 63 , 0.05
Lesion length (mm) 9 6 7 12 6 11 , 0.05
Ostial location 22% 26% 0.013
Distal anastomotic site 15% 18% 0.03
Restenotic lesion 28% 23% 0.003
Thrombus 16.4% 11% , 0.0001
Graft degeneration 36.5% 60.2% , 0.05
Total occlusion 5% 9% , 0.0001
Reference vessel (mm) 3.2 6 0.8 3.3 6 0.8 0.005
Pre-intervention MLD (mm) 1.0 6 0.7 1.0 6 0.7 NS
Pre-intervention DS (%) 69 6 18 68 6 20 NS
Final MLD (mm) 2.8 6 0.9 2.9 6 0.8 NS
Final DS (%) 14 6 20 12 6 16 0.012
Data are presented as the mean value 6 SD or percentage of patients.
DS 5 diameter stenosis; MLD 5 minimal lumen diameter; NS 5 not significant.
Table 3. Angioplasty Devices
1990 to 1994
(n 5 1,412)
1995 to 1998
(n 5 1,315)
p
Value
Balloon only 22.4% 19.7% 0.086
Atheroablative devices 22.2% 14.1% , 0.0001
Directional atherectomy 5.1% 0.2% , 0.0001
Transluminal extraction
catheter
11.2% 1.3% , 0.0001
Excimer laser 5.9% 12.6% , 0.0001
Stent 54% 64.9% , 0.0001
Data are presented as the percentage of patients.
Table 4. In-Hospital Outcomes
1990 to 1994
(n 5 1,055)
1995 to 1998
(n 5 964)
Procedural success 96.6% 96.1%
Major complications 3.1% 2.9%
Death 1.9% 2.2%
Q-wave MI 1.4% 0.5%
Emergency
CABG
0.3% 0.8%
Non–Q-wave MI* 16% 18%
No reflow 2.2% 2.6%
*Creatine kinase-MB isoenzyme level greater than five times the upper limit of
normal. Data are presented as the percentage of patients. P values were not
significantly different between the groups for any event.
CABG 5 coronary artery bypass graft surgery; MI 5 myocardial infarction.
Table 5. One-Year Clinical Outcomes
1990 to 1994
(n 5 1,044)
1995 to 1998
(n 5 942) p Value
Event-free survival 59.1% 70.7% , 0.0001
Death 11.3% 6.1% , 0.0001
Nonfatal MI 0.4% 0% NS
TLR 23.6% 16.4% , 0.0001
Repeat angioplasty 20.2% 12.5% 0.0002
Repeat CABG 3.6% 3.8% NS
Non-TLR 6.8% 7.4% NS
Data are presented as the percentage of patients.
NS 5 not significant; TLR 5 target lesion revascularization; other abbreviations
as in Table 4.
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tion between the strategies and the results do not provide
mechanistic insights for the results, the findings suggest that
high-risk SVG lesions may still be approached with mini-
mal instrumentation and liberal use of stents for better
long-term results.
Previous studies. Initial experience with angioplasty of
SVG lesions was discouraging, mainly because of frequent
distal embolization and the high incidence of major isch-
emic complications associated with distal embolization
(1,2). Even new angioplasty devices were not helpful, and
some were actually associated with greater procedural com-
plication rates (9). Furthermore, abciximab was initially
reported to improve procedural outcomes in a small sub-
group study of the Evaluation of IIb/IIIa platelet receptor
antagonist 7E3 in Preventing Ischemic Complications
(EPIC) trial (10). However, there has been no large
randomized series conclusively showing a benefit with this
potent pharmacologic agent in SVGs.
The only reports showing consistently improved results,
compared with conventional SVG angioplasty, have been
stent experiences (11,12). Wong et al. (11) showed that
Palmaz-Schatz stents could successfully treat 97% of focal
SVG lesions and result in a restenosis rate of ;30% at six
months. Randomized stenting of focal SVG lesions (12)
also showed significantly improved procedural results com-
pared with balloon angioplasty (97% vs. 86%), as well as
reduced restenosis rates (37% vs. 46%).
Evolving strategies at the Washington Hospital Center.
Because of the discouraging results with balloon angioplasty
of SVG lesions, we initially tested the hypothesis that
removal of the lesion components with atherectomy and
extraction devices might reduce the risk of distal emboliza-
tion. However, in agreement with the histologic finding
that SVG lesions are tenuous, we observed that the risk of
distal embolization appeared to increase with more instru-
mentation within the graft, especially with bulky devices.
Thus, we revised our hypothesis and strategy starting in
1995, when we essentially eliminated the use of bulky
atheroablative devices, except for selective use of the Exci-
mer laser in degenerated SVGs and increased stent use,
especially “direct” stenting without pre- or post-stent bal-
loon angioplasty. Furthermore, we have limited the stent
implantation pressure to ,10 atm to reduce the risk of distal
embolization from plaque material squeezed through the
stent struts, except for fibrotic lesions requiring higher
pressure for complete stent expansion. In a small percentage
of patients (;5%) who could not tolerate any further
ischemic insult, as judged by the operators, we adopted the
“staged” procedure (6). These patients underwent the initial
procedure with transluminal extraction catheter to create a
2.0- to 2.5-mm channel (with 50% residual stenosis in 4- to
5-mm SVGs). Then, the patients were discharged home on
warfarin (Coumadin) therapy and returned for more defin-
itive procedure with stents six weeks later. This approach
did result in avoidance of distal embolization during the
initial procedure (6). More recently, glycoprotein IIb/IIIa
inhibitors have been used (8.7%), with one-third prophy-
lactic use and two-thirds use in “rescue” situations when
there was a procedural complication. We cannot definitively
conclude whether these strategies have reduced procedural
complications, as no large-scale randomized study has been
performed in SVGs. However, considering the fact that the
recent group had significantly more unfavorable lesion
characteristics, especially a higher incidence of graft degen-
eration, compared with the earlier group (60.2% vs. 36.5%),
the comparable procedural results should be viewed as
encouraging.
The other discouraging fact, even after initially successful
SVG angioplasty, has been the high incidence of late cardiac
events, including high late mortality rate (approaching 10%
within one year after SVG angioplasty). The potential
reasons for this observation include more comorbid condi-
tions in these patients (e.g., higher prevalence of previous
MI and lower ejection fraction), high restenosis rates and
rapid progression of nontarget lesions. On the basis of
previous registry findings (11) and the only randomized
study comparing balloon and stent use in SVGs (12), we
have attempted to implant stents whenever feasible since
1995. This approach has included angiographically border-
line lesions in the SVG being treated (13), as well as in
selected distal anastomotic lesions (7). The results of the
current study show that this approach may reduce late
mortality and the need for TLR.
Predictors of late cardiac events and TLR. Multivariate
analysis showed that certain factors were predictive of late
cardiac events during both periods, with unstable angina
negatively associated with late events and stent use confer-
ring protection. Although diabetes mellitus was predictive
Table 6. Multivariate Predictors of Late Cardiac Events
1990 to 1994 1995 to 1998
p Value
OR
(95% CI) p Value
OR
(95% CI)
Unstable angina 0.015 1.6 (1.1–2.2) 0.015 1.5 (1.1–2.1)
Diabetes mellitus 0.023 1.4 (1.1–1.9) — —
Ostial location — — 0.0003 1.9 (1.3–2.6)
Stent use 0.0001 0.6 (0.4–0.8) 0.002 0.6 (0.5–0.8)
CI 5 confidence interval; OR 5 odds ratio.
Table 7. Multivariate Predictors of Target Lesion
Revascularization
1990 to 1994 1995 to 1998
p Value
OR
(95% CI) p Value
OR
(95% CI)
Ostial location 0.01 1.5 (1.1–2.1) 0.0003 2 (1.4–2.9)
Age 0.0008 0.98 (0.96–0.99) — —
Final MLD 0.03 0.8 (0.71–0.98) — —
Stent use — — 0.0014 0.6 (0.4–0.8)
MLD 5 minimal luminal diameter; other abbreviations as in Table 6.
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of late cardiac events in the early group, it was no longer a
predictor in the recent group, possibly due to the “neutral-
izing” effects of stents. Ostial location was a negative
predictor in the recent group, suggesting that even stents do
not prevent late adverse sequelae at this location.
Indeed, ostial location was the only consistent predictor
of TLR in both groups. In the early period, age was a weak
negative predictor of TLR, possibly because of reluctance of
the cardiologists to recommend repeat procedures in elderly
patients. Final minimal lumen diameter was an inverse
predictor of TLR in the early period, probably because of
less than optimal stent implantation techniques. The sub-
optimal stent implantation techniques, as well as the use of
articulated coronary stents in the early period, may explain
why stents were not a predictor of reduced TLR. In the
recent group, stent use without central articulation provided
strong protection against TLR.
Clinical implications and future directions. The present
study shows that despite more unfavorable lesion character-
istics, we can treat SVG lesions with comparable early
results and improved long-term outcomes, mainly by de-
ploying stents in all suitable SVG lesions. Aorto-ostial
lesions still present a difficult subset of lesions associated
with high restenosis rates, despite stenting. Promising
results with radiation therapy (14) may further improve late
outcomes in this unfavorable lesion subset. Future efforts
with distal protection device (15) may also improve the
procedural and late outcomes in these challenging lesions.
Finally, at present, stents are without question the treatment
of choice in SVG lesions.
Study limitations. The main limitation of this study is that
it is a retrospective comparison of the two periods and does
not include any randomization of different treatment strat-
egies. Furthermore, there was no prospective, consistent
strategy adopted during any period. Thus, it is difficult to
determine which, if any, of the evolving treatment options
contributed to the favorable results. For these reasons, it is
impossible to recommend the adoption of these strategies to
the interventional cardiology community. Finally, these
results were obtained before the exciting recent develop-
ments of brachytherapy and distal protection devices. It is
conceivable that the results can be even further improved
with these treatment options.
Conclusions. This study shows that continuing efforts to
prevent distal embolization and reduce late cardiac events
with stents may provide acceptable procedural and long-
term outcomes in patients with SVG disease. Future efforts
to address high-risk subsets, such as those with unstable
angina or ostial lesions, may further improve results in SVG
population.
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